BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst to Report First Quarter 2025 Financial Results on May 5

21 4 2025 07:00:19 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 4 2025 07:00:08 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

02 4 2025 16:01:05 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 3 2025 07:00:51 提供 Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

24 2 2025 07:00:48 提供 Nasdaq GlobeNewswire

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

24 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

20 2 2025 11:25:06 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

19 2 2025 10:50:17 提供 NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

19 2 2025 07:00:51 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

18 2 2025 09:45:16 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

14 2 2025 12:47:37 提供 NetDania Notify

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

12 2 2025 07:00:56 提供 Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

10 2 2025 08:30:43 提供 Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

10 2 2025 07:00:05 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

05 2 2025 10:18:33 提供 NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 2 2025 07:00:08 提供 Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

10 1 2025 07:00:30 提供 Nasdaq GlobeNewswire

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 1 2025 07:00:57 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2025 07:00:46 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 12 2024 16:15:10 提供 Nasdaq GlobeNewswire